News and commentary from the world of gastroenterology and hepatology
— News and commentary from the world of gastroenterology and hepatology
by Ian Ingram, Managing Editor, MedPage Today
May 21, 2026
• 2 min read
Compared to people without liver steatosis, those with the condition had greater noncalcified coronary plaque burden and nearly twice the risk for major cardiovascular events, an analysis of the multicenter PROMISE study showed. (Clinical Gastroenterology and Hepatology)
FDA approves Immgolis as first golimumab biosimilar for ulcerative colitis, RA
‘Strikingly better’: Co-antibody combination tops golimumab, guselkumab in refractory IBD
BMI, other markers could address steatotic liver disease screening ‘blind spot’ in youth
Pharmalittle: We're reading about a Lilly obesity drug trial, statistics for an Alzheimer's drug, and more
Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
Brepocitinib approval for dermatomyositis would be ‘highlight of the derm-rheum world’
Ibrance's would-be successors, the data that helped sell Tubulis to Gilead, and more at ASCO
VIDEO: Updates on semaglutide use in Alzheimer’s disease
Design Therapeutics' Friedreich ataxia data; Vincentage's obesity results from China
News and commentary from the world of gastroenterology and hepatology
GSK’s recent deal to license out a rare liver disease drug just got sweeter.
The FDA has approved golimumab-sldi as the first interchangeable biosimilar to Simponi for ulcerative colitis. Golimumab-sldi…
Adults with moderate to severe psoriasis and overweight or obesity were more likely to achieve complete skin clearance plus…
Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout
CHICAGO — Combining golimumab and guselkumab into JNJ-78934804, a fixed-dose co-antibody therapy, helped overcome treatment…
